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Abstract
Background:  This phase II study evaluated the efficacy and safety of gemcitabine (G) plus
paclitaxel (T) as first-line therapy in recurrent or metastatic breast cancer.
Methods: Patients with locally, recurrent or metastatic breast cancer and no prior chemotherapy
for metastatic disease received G 1200 mg/m2 on days 1 and 8, and T 175 mg/m2 on day 1 (before
G) every 21 days for a maximum of 10 cycles.
Results: Forty patients, 39 metastatic breast cancer and 1 locally-advanced disease, were enrolled.
Their median age was 61.5 years, and 85% had a World Health Organization performance status
(PS) of 0 or 1. Poor prognostic factors at baseline included visceral involvement (87.5%) and ≥2
metastatic sites (70%). Also, 27 (67.5%) patients had prior adjuvant chemotherapy, 25 of which had
prior anthracyclines. A total of 220 cycles (median 6; range, 1–10) were administered. Of the 40
enrolled patients, 2 had complete response and 12 partial response, for an overall response rate of
35.0% for intent-to-treat population. Among 35 patients evaluable for efficacy the response rate
was 40%. Additional 14 patients had stable disease, and 7 had progressive disease. The median
duration of response was 12 months; median time to progression, 7.2 months; median survival, 25.7
months. Common grade 3/4 toxicities were neutropenia in 17 (42.5%) patients each, grade 3
leukopenia in 19 (47.5%), and grade 3 alopecia in 30 (75.0%) patients; 1 (2.5%) patient had grade 4
thrombocytopenia.
Conclusion:  GT exhibited encouraging activity and tolerable toxicity as first-line therapy in
metastatic breast cancer. Phase III trials for further evaluation are ongoing.
Background
In most developed countries, breast cancer is second only
to lung cancer as the most common cause of cancer-
related death in women, [1] and thus represents a serious
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health-care problem. Systemic therapy for patients with
metastatic breast cancer (MBC) consists of hormonal ther-
apy and cytotoxic chemotherapy. Anthracyclines such as
doxorubicin and epirubicin can yield response rates of
around 20% to 40% in MBC patients when used as single
agents, and up to 60% when given as part of combination
regimens [2]. However, the efficacy achieved with anthra-
cyclines comes at the cost of high toxicity. New cytotoxic
drugs with high activity, such as taxanes (paclitaxel and
docetaxel), vinorelbine, gemcitabine, and capecitabine
(all of which were introduced in the 1990s), have raised
the hopes of patients with MBC to experience higher effi-
cacy with tolerable toxicity. Recent studies suggest that
combination chemotherapy may be more effective than
single-agent therapy [3,4].
Paclitaxel is a mitotic spindle poison that promotes
microtubular aggregation and interferes with essential cel-
lular functions such as mitosis, cell transport, and cell
motility [5,6]. It has shown remarkable activity in both
chemonaive and anthracycline-resistant patients with
MBC. Single-agent paclitaxel produced response rates of
32% to 62% in MBC patients not pretreated with chemo-
therapy, and from 6% to 48% in those who relapsed after
treatment with anthracyclines [7-12].
Gemcitabine (difluorodeoxycytidine), an analog of cyto-
sine arabinoside (ara-C), is a pyrimidine antimetabolite
[13] that acts as a competitive substrate for incorporation
into DNA where it brings about chain termination. It has
undergone considerable testing for various malignancies
and has exhibited activity in many solid tumors, including
advanced or MBC. In MBC, single-agent gemcitabine has
yielded response rates of up to 37% in chemonaive
patients, [14-16] and 26% in those pretreated with
anthracyclines [16-18]. Median progression-free survival
with gemcitabine monotherapy was in the range of 2 to 6
months [14-20].
Preclinical studies of gemcitabine and paclitaxel have sug-
gested that mechanisms of resistance affecting one drug
may not have a significant effect on the other [21,22]. In
pharmacokinetic studies, paclitaxel increased accumula-
tion of dFdCTP, which might enhance the antitumor
activity of gemcitabine in clinical studies [23]. The admin-
istration of paclitaxel prior to gemcitabine indicated an
additive effect and was considered a better choice than a
reverse sequence [24]. Study of this combination in treat-
ment of ovarian cancer has also indicated that paclitaxel
before gemcitabine is a less toxic sequence[25].
In summary, gemcitabine and paclitaxel are 2 agents with
unique mechanisms of action, noncross-resistance, and
the potential for synergistic antitumor activity. They are
both active as single agents in the treatment of patients
with MBC, and when used together, the treatment was
well tolerated with promising activity [26-28]. A 3-week
schedule of gemcitabine/paclitaxel (with gemcitabine
administered on days 1 and 8, and paclitaxel on day 1)
was tolerated better than a 4-week schedule [29,30].
Based on this information, we initiated a phase II, open-
label, multicenter, nonrandomized study of gemcitabine
in combination with paclitaxel given as first-line therapy
in patients with recurrent or MBC. The primary objectives
were to evaluate the response rate and duration of
response. The secondary objectives were to assess safety,
and to determine the time to disease progression and
overall survival of this combination.
Methods
Eligibility criteria
Patients with unresectable, locally recurrent, or metastatic
breast cancer that was not amenable to surgery or radia-
tion of curative intent were enrolled. The qualifying
patients were required to have histologically or cytologi-
cally confirmed breast carcinoma, with bidimensionally
measurable lesions at least 1 cm × 1 cm (or 2 cm × 2 cm
by physical examination). Prior chemotherapy was not
allowed unless patients had local or metastatic relapse
more than 12 months after the end of prior adjuvant or
neoadjuvant chemotherapy. Patients could not have
received previous therapy with gemcitabine or a taxane.
Patients aged 18 to 75 years were further required to have
a World Health Organization (WHO) performance status
of 0 to 2, and an estimated life expectancy of at least 12
weeks. It was also necessary for patients to have adequate
bone marrow function (absolute granulocyte count
[AGC] ≥1.5 × 109/L, platelet count ≥100 × 109/L, and
hemoglobin ≥90 g/L), adequate liver function (bilirubin
≤1.5 times the upper limit of normal [ULN], alanine
transaminase [ALT] and aspartate transaminase [AST] ≤3
times ULN, or up to 5 times the ULN in patients with
known metastatic liver disease), and adequate renal func-
tion (creatinine ≤2.5 times above the ULN). Prior radia-
tion was permitted only if measurable disease was outside
a previously irradiated area, if radiotherapy was not given
to more than 50% of bone marrow volume, and if it was
terminated at least 4 weeks prior to enrollment. Prior
bone marrow transplantation, as adjuvant therapy, was
allowed, and antitumoral hormonal treatment had to be
terminated before enrollment. Patients with inflamma-
tory breast cancer without evidence of metastatic disease,
as well as patients who were pregnant, who had a neuro-
logical disorder WHO grade ≥2, or serious concomitant
systemic disorders incompatible with the study could not
participate. Patients were also excluded for active cardiac
disease not controlled by therapy and/or myocardial inf-
arction within the previous 6 months. Additional exclu-
sion criteria included active infection, presence of severeBMC Cancer 2005, 5:151 http://www.biomedcentral.com/1471-2407/5/151
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psychiatric disease, or second malignancy (except in situ
carcinoma of the cervix or adequately treated basal cell
carcinoma of the skin).
All the patients who presented and met eligibility criteria
were entered into the study. Physicians obtained signed
informed consent from all patients prior to administering
treatment. The study was conducted per the guidelines of
good clinical practice and the Declaration of Helsinki.
Treatment plan
Paclitaxel 175 mg/m2  was administered intravenously
(iv), before gemcitabine, on day 1 over a period of 3
hours. Gemcitabine 1200 mg/m2 was given iv on days 1
and 8 over a period of 30 to 60 minutes (ideally 30 min-
utes), followed by a 1-week rest period. Each 21-day (3-
week) period defined a cycle of therapy. Multiple injec-
tions of both drugs were administered for a total of at least
2 cycles unless it was clearly not in the patient's best inter-
est to continue. Treatment was stopped in case of intoler-
able toxicity or disease progression. Additional cycles, up
to a maximum of 10, could be administered in patients
exhibiting a complete response (CR) or partial response
(PR). All patients were premedicated with dexamethasone
and chlorpheniramine, or clemastine or ranitidine or
cimetidine prior to paclitaxel administration to prevent
severe hypersensitivity reactions.
Dose adjustments during treatment (day 8) were made
based on weekly AGC and platelet counts performed
within 24 hours prior to the start of therapy and clinical
assessment of nonhematologic toxicities. For an AGC <1.0
(×109/L) and/or a platelet count <75 (×109/L) or a WHO
nonhematologic toxicity grade 3 (except nausea/vomiting
and alopecia) or grade 4, doses of gemcitabine were held.
A dose missed for any reason was not given at a later time.
The day-1 dose of each subsequent cycle depended on the
toxicity seen in the previous cycle. The treatment was
delayed until the AGC returned to 1.5 and the platelet
count to 100. Otherwise, full doses of both drugs were
given, except in patients with WHO grade 4 granulocyto-
penia lasting for more than 1 week, or grade 4 neutrope-
nia associated with fever ≥38.5°C, or grade 4
thrombocytopenia. In these circumstances, after recovery,
the day 1 and 8 doses of both drugs were given at 75% of
the dose given on day 1 of the last cycle. The observed
nonhematologic toxicities (except alopecia and vomiting)
had to return to WHO grade 0 to 1, or baseline conditions,
before resuming injections of both drugs. Doses in subse-
quent cycles were reduced to 75% or held for any grade 3
nonhematologic toxicity (except nausea/vomiting and
alopecia), and were reduced to 50% or held for any grade
4 nonhematologic toxicity. Patients were withdrawn from
the study after 3 weeks of treatment delay due to any tox-
icity.
Baseline and treatment assessments
Assessments performed at baseline and throughout the
study included history and physical examination (includ-
ing weight and height), WHO performance status, and
tumor measurement of palpable or visual lesions. Radio-
logical tests of computed tomography (CT) scan, mag-
netic resonance imaging (MRI), or nuclear medicine scan
were used, if necessary, for tumor measurement of lesions
not evaluable by other imaging modalities. Chest x-rays
were used in patients with chest metastasis. Full blood
count (with differential and platelet counts), blood chem-
istries, electrocardiogram, and vital signs were done for all
patients before and at regular intervals during the study.
Additionally, coagulation studies were assessed as appro-
priate and the number of units required for transfusions
every 4 weeks.
All patients who received at least 2 cycles of therapy and 1
radiologic evaluation were eligible for the efficacy analysis
which was done based on WHO criteria. Complete
response (CR) was defined as the disappearance of all
known disease, and PR was defined as at least a 50%
decrease in the total tumor size of the lesions, both deter-
mined by two observations not less than 4 weeks apart,
and without appearance of new lesions. Stable disease
(SD) was documented if a 50% decrease in total tumor
size could not be established, nor a 25% increase in the
size of one or more measurable lesions demonstrated.
Progressive disease (PD) was defined as an increase ≥25%
in measurable or evaluable tumor size and/or the appear-
ance of new tumor sites. The safety analysis was per-
formed on data from all patients who received at least 1
dose of the study drugs. The same assessment method
used to determine the disease status at baseline was used
consistently throughout the study for efficacy evaluation.
Patients were clinically evaluated for response at the start
of each cycle. Every 3 cycles during therapy, then every 3
months until disease progression, patients were assessed
by radiologic imaging studies and chest radiography. Sur-
vival was measured from time of first-dose administration
until the date of death. Time to disease progression was
calculated from the administration of the first dose until
the date of progression. Overall duration of response was
measured from the first day of treatment to the date of the
first observation of progressive disease. Toxicity ratings,
based on WHO criteria, were assessed before the begin-
ning of each next cycle.
Data analysis
The response rate for this study was anticipated to be in
the region of 40%. If 35 patients qualified for the efficacy
analysis and 14 responses (40%) were observed, then theBMC Cancer 2005, 5:151 http://www.biomedcentral.com/1471-2407/5/151
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95% confidence interval (CI) would be 26%–54%. The
evaluability criteria for efficacy analysis were predefined
in the protocol as; any patient who received at least 2
cycles of therapy and one radiological evaluation. It was
anticipated that approximately 10% of the patients
recruited might not qualify for the efficacy analysis. Con-
sequently, this study intended to recruit 39 patients.
For the primary analysis, a 95% CI for the true response
rate was calculated using the normal approximation to the
binomial distribution. Estimates of duration of response
and time to disease progression were calculated using the
Kaplan-Meier method, with medians and quartiles
derived from these estimates.
Results
Patient characteristics
From October 1999 to December 2001, a total of 40
female patients were entered, and all were enrolled
(received study treatment). These patients had a median
age of 61.5 years (range, 30–76 years), and the majority
(85%) had a WHO performance status of 0 or 1. The base-
line patient and disease characteristics are summarized in
Table 1. This patient population presented with multiple
poor prognostic factors. Overall, 39 (97.5%) patients pre-
sented with metastatic disease, and 35 (87.5%) had vis-
ceral involvement. Eight (20.0%) patients reported both
liver and lung metastases at baseline, and 28 (70.0%)
patients had at least 2 sites of metastatic disease at base-
line. Three patients had 4 or more tumor burden sites,
including 1 patient with 6 sites of metastatic disease. Of
the 35 patients with known hormone receptor status, 12
(34.3%) were negative for estrogen/progesterone recep-
tors (ER/PR). In addition, 27 (67.5%) patients had
received previous adjuvant chemotherapy, 25 of whom
had prior anthracyclines. A total of 24 (60.0%) patients
had received both adjuvant chemotherapy and hormonal
therapy.
Response and time-to-event measures
Among the 40 patients enrolled, there were 2 CR and 12
PR. Based on an Intent-to-treat analysis, the overall
response rate was 35.0%. An additional 14 (35.0%)
patients had stable disease, and 7 patients (17.5%) had a
best response of progressive disease. Of the remaining 5
patients, 4 did not undergo further evaluation of their
lesions after baseline, and 1 patient did not have histolog-
ically or cytologically proven breast carcinoma. As per the
predefined criteria in the protocol these 5 patients were
not eligible for efficacy analysis.
According to per-protocol efficacy analysis, 2 CR and 12
PR, gave an overall response rate of 40.0% (14/35) (95%
CI, 23.8%–56.2%). The response rate was lower among
22 patients who had prior anthracycline treatment com-
pared to the remaining 13 with no anthracycline exposure
(27.3% vs 61.5%) (Table 2).
At the time of this analysis, the median follow-up time
(the period from patient enrollment to last visit) was 13.7
months (range, 1.6–28.3 months). A total of 14.3% (n =
5) of patients were censored for the estimate of duration
of response because they were alive and progression-free,
or lost to follow-up at the time of the analysis. The esti-
mate of median duration of response was 12.0 months
(95% CI, 10.0–15.0 months). The probability of duration
of response lasting at least 9 and 12 months was estimated
as 78.6% (95% CI, 57.1%–100%) and 47.1% (95% CI,
20.0%–74.3%), respectively. The estimate for median
time to progressive disease was 7.2 months (95% CI, 4.6–
10.0 months). The progression-free probability at 6 and 9
months was estimated as 62.9% (95% CI, 46.8%–78.9%)
and 40.0% (95% CI, 23.8%–56.2%), respectively. A total
of 11.4% (n = 4) of patients who were alive and had not
progressed, or were lost to follow-up, were censored for
this analysis. The most common sites of disease progres-
sion were liver and lung, which were the most commonly
involved sites at baseline. Fourteen patients had died, and
the remaining 60% (n = 21) of patients who were alive or
lost to follow-up were censored for the survival analysis.
Table 1: Patient characteristics (N = 40)
Patients entered and enrolled 40
Median age, years (range) 61.5 (30–76)
WHO performance status, n (%)
0 18 (45.0)
1 16 (40.0)
26  ( 1 5 . 0 )
Histology, n (%)
Breast 1 (2.5)
Ductal breast 31 (77.5)
Lobular breast 8 (20.0)
Number of metastatic sites, n (%)
1 12 (30.0)
2 21 (52.5)
34  ( 1 0 . 0 )
≥4 3 (7.5)
Metastatic sites of diseasea, n (%)
Visceral 35 (87.5)
Liver 26 (65.0)
Lung (including pleura) 17 (42.5)
Nonvisceral only 5 (12.5)
Menopausal status, n (%)
Pre-menopausal 20 (50.0)
Menopausal 8 (20.0)
Post-menopausal 10 (25.0)
Unknown 2 (5.0)
Estrogen/progesterone receptors, n (%)
Positive 23 (57.5)
Negative 12 (30.0)
Unknown 5 (12.5)
aPatients may be counted in more than one category.BMC Cancer 2005, 5:151 http://www.biomedcentral.com/1471-2407/5/151
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The estimate of median survival was 25.7 months (95%
CI, 14.7-xx months). The probability of surviving beyond
12 and 18 months was estimated as 74.0% (95% CI,
59.3%–88.6%) and 62.0% (95% CI, 44.5%–79.5%),
respectively.
Dose administration
All 40 patients received at least 1 cycle of therapy, for a
total of 220 cycles. The median number of cycles given
was 6 (range, 1–10 cycles). Three (7.5%) patients com-
pleted the study and received the maximum number of 10
treatment cycles. The most frequently cited reason for dis-
continuation from the study was progressive disease (14
patients; 35.0%), as indicated by radiologic and/or physi-
cal assessment. Five (12.5%) patients discontinued the
study because of adverse events, and 1 patient died in
cycle 2 due to progression.
Patients received mean doses of 681.0 mg/m2 gemcitabine
and 56.7 mg/m2 paclitaxel per week, which were 85.1%
and 97.2% of the planned weekly mean doses, respec-
tively. There were 48 (10.9% of doses administered) dose
omissions and 1 (0.2%) dose reduction of gemcitabine,
and 4 (1.8%) omissions and 4 (1.8%) reductions of pacl-
itaxel. Neutropenia was the most frequent cause of gem-
citabine dose omission (35 of 48 doses omitted; 72.9%).
All gemcitabine dose omissions due to neutropenia
occurred on day 8, and the majority of dose omissions (22
of the 35 doses) occurred during the first 3 cycles. Par-
esthesia was the cause of 2 paclitaxel dose reductions and
all 4 paclitaxel dose omissions. Overall, there were 34
cycle delays of administration of gemcitabine plus paclit-
axel. The clinically relevant reasons for cycle delays
included hepatitis in 1 patient (delay at cycles 2 and 3),
pyrexia in 2 patients, neutropenia in 3 patients, and asthe-
nia, edema, paresthesia, and pleural disorder in 1 patient
each.
Toxicity
All 40 patients entered into the study were evaluable for
toxicity. The WHO grade 3 and 4 toxicities observed dur-
ing this study were primarily hematologic (Table 3). These
included grade 3 and 4 neutropenia in 17 (42.5%)
patients each, grade 3 leukopenia in 19 (47.5%) patients,
grade 3 anemia in 2 (5.0%) patients, and grade 3 and 4
thrombocytopenia in 1 (2.5%) patient each. Although 2
patients with grade 4 neutropenia had concurrent fever,
neither patient was hospitalized for febrile neutropenia.
The patient who reported grade 4 thrombocytopenia
required a platelet transfusion. A total of 8 units of red
Table 2: Summary of best tumor response according to prior anthracycline exposure
No. of Pts No. of Responders Percent of Pts 95% CI
Evaluable patients 35 14 40.0% (23.8%–56.2%)
Prior anthracycline exposure
Yes 22 6 27.3% (8.7%–45.9%)
No 13 8 61.5% (35.1%–88.0%)
CI = confidence interval.
Table 3: Summary of maximum WHO toxicity grades (N = 40)
Grade 3 Grade 4
Toxicity n (%) n (%)
Hematologic
Anemia 2 5.0 0 0
Leukopenia 19 47.5 0 0
Neutropeniaa 17 42.5 17 42.5
Thrombocytopenia 1 2.5 1 2.5
Non-hematologic
Cardiac function 1 2.5 0 0
Alopecia 30 75.0 0 0
Infection 1 2.5 0 0
Nausea/vomiting 1 2.5 0 0
Peripheral neurotoxicity 3 7.5 0 0
aSegmented neutrophils have been converted to WHO scores using granulocyte count criteria.BMC Cancer 2005, 5:151 http://www.biomedcentral.com/1471-2407/5/151
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blood cells were given; the recipients included both of the
patients with grade 3 anemia.
No grade 4 nonhematologic toxicities were reported dur-
ing the study. The most common grade 3 toxicity was alo-
pecia in 30 (75.0%) patients. Three (7.5%) patients
reported grade 3 peripheral neurotoxicity, which occurred
during later cycles (cycles 4 through 8). Grade 2 neurotox-
icity was experienced by 12 (30.0%) patients. There was
only 1 report of a grade 2 pulmonary toxicity that was
described as dyspnea. One patient, who was previously
treated in the adjuvant setting with epirubicin, 5-FU, and
cyclophosphamide combination therapy and radiother-
apy, reported cardiac toxicity. The patient was hospital-
ized for severe dyspnea and was diagnosed with
arrhythmia and tachycardia. The patient also had grade 3
infection described as severe sepsis. The patient discontin-
ued the study due to cardiac rhythmic events.
There were 2 deaths, 1 of which occurred on-study and 1
during the 30-day follow-up period after administration
of the last dose of study drug. Both of the deaths were con-
sidered related to disease progression. There were no
deaths due to study drug toxicity.
Discussion
The results of this phase II trial demonstrated that the
combination of gemcitabine 1200 mg/m2 on days 1 and
8, plus paclitaxel 175 mg/m2 on day 1, administered in a
21-day cycle was effective in patients with unresectable,
locally recurrent or MBC. In a first-line setting, this regi-
men resulted in a response rate of 40.0% (35.0% for
Intent-to-treat population), with a complete response rate
of 5.7%. The response rate in the patients previously
exposed to anthracyclines was lower than in those not
exposed to anthracyclines. The median duration of
response was 12 months. In addition, the median time to
progressive disease was 7.2 months, which was higher
than that obtained with either single agent. Although the
overall survival data are not fully mature, the median sur-
vival time of 25.7 months is also quite promising. This is
a phase II non-randomized trial, and hence there are lim-
itations in interpreting these results, however the efficacy
results compare favorably with those seen with single-
agent paclitaxel or single-agent gemcitabine in
MBC,[11,14,31,32] and are also comparable with the
results of this combination seen in other trials (see Table
4). It is important to note that these efficacy results were
achieved in a patient population with multiple poor prog-
nostic factors such as: visceral involvement, at least 2 sites
of metastatic disease at baseline, negative hormone recep-
tor status, and prior exposure to chemotherapy, including
anthracyclines, in an adjuvant setting.
Since the initiation of this trial, the combination of gem-
citabine and paclitaxel has been tested in different doses
and schedules, as well as in various patient populations
with different levels of exposure to prior chemotherapy. In
a phase I dose-finding study,[33] fixed doses of gemcitab-
ine (1000 mg/m2) on days 1 and 8 were administered
with escalating doses of paclitaxel (range, 90–270 mg/m2)
on day 1 of a 21-day cycle in patients with pretreated MBC
or ovarian cancer. At the paclitaxel dose level of 270 mg/
m2, the dose-limiting toxicities (DLT) of grade 4 neutrope-
nia and thrombocytopenia were noted, but there were no
unexpected toxicities. Among 30 evaluable patients with
MBC, 4 CRs (13%) and 12 PRs (40%) were observed, for
an overall response rate of 53%. The median duration of
response was 7.2 months.
In another study, heavily pretreated MBC patients were
treated with 2500 mg/m2 gemcitabine and 135 mg/m2
Table 4: Phase II studies of gemcitabine/paclitaxel in patients with advanced or metastatic breast cancer
Author Regimen No. of 
Pts
ORR % (CR %) Median TTP 
(mos)
Comments
Vici et al26 G 1500 mg/m2 d1, 15 + T150 mg/
m2 d1, 15 q4wks
20 45% (10%) 8 Heavily pretreated pts; supported 
with G-CSF
Colomer et al27 G 2500 mg/m2 d1 + T150 mg/m2 
d1 q2wks
43 68% (21%) 9 Previously treated pts; hematologic 
toxicity
Delfino et al28 G 1200 mg/m2 d1, 8 + T 175 mg/
m2 d1 q3wks
45 67% (22%) 11 Chemonaïve pts; mild hematologic 
toxicity; manageable toxicity
Sanchez-Rovira et al29 G 2500 mg/m2 d1, 15 + T 135 mg/
m2 d1, 15 q4wks
44 45% (7%) 7 Previously treated pts; hematologic 
and neurologic toxicities
Murad et al30 G 1000 mg/m2 d1, 8 + T 175 mg/
m2 d1 q3wks
29 55% (17%) 8 Heavily pretreated pts; 28-day 
reduced to a 21-day schedule due to 
hematologic toxicity
Genot et al (current 
study)
G 1200 mg/m2 d1, 8 T 175 mg/m2 
d1 q3wks
40 40% (5.7%) 7.2 No prior treatment for metastatic 
disease, neutropenia prominent, 
other toxicities mild
ORR = overall response rate; CR = complete response; TTP = time to progression; mos = months; G = gemcitabine; T = paclitaxel.BMC Cancer 2005, 5:151 http://www.biomedcentral.com/1471-2407/5/151
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paclitaxel, both of which were given on days 1 and 15
[29]. The overall response rate achieved was 45%. The
median time to progression was 7 months, and overall
survival time was 11 months. However, 34% of the
patients needed growth factors. In a similar trial, Vici et al
[26] used 1500 mg/m2 gemcitabine and 135 mg/m2 pacl-
itaxel on days 1 and 15 every 4 weeks in heavily pretreated
advanced breast cancer patients who had received 1 to 4
cycles of prior chemotherapy. Although the doses were
lower than those used in the Sanchez-Rovira trial, patients
were supported with G-CSF injections. In the preliminary
results, the overall response rate in 20 evaluable patients
was 45% with a median time to progression of 8 months.
Murad et al [30] evaluated gemcitabine plus paclitaxel in
heavily pretreated MBC patients with history of 2 or 3
relapses following treatment with anthracycline-contain-
ing regimens. The initial schedule was gemcitabine (1000
mg/m2) on days 1, 8, and 15 plus paclitaxel (175 mg/m2)
on day 1, given every 4 weeks. However, due to occurrence
of unacceptable toxicity (thrombocytopenia) in the first 5
patients, the schedule was modified to every 3 weeks with
gemcitabine given on days 1 and 8. The modified regimen
was well tolerated, with a significantly lower incidence of
grade 3 or 4 thrombocytopenia (18.5% in the day-28
schedule vs 5.4% in the day-21 schedule), and resulted in
an overall response rate of 55%, with 17% complete
responses. The median response duration was 8 months,
and the median overall survival was 12 months.
The combination of gemcitabine and paclitaxel was also
evaluated as first-line treatment of advanced or MBC.
Forty-three chemonaive patients with histologically con-
firmed metastatic breast carcinoma received paclitaxel
150 mg/m2 followed by gemcitabine 2500 mg/m2, both
on day 1 of a 2-week cyclem [27]. Among the 38 evaluable
patients, the overall response rate was 68%, with moder-
ate neutropenia seen in 32% of patients.
Delfino et al [28] assessed the efficacy and toxicity of the
gemcitabine/paclitaxel combination in a first-line setting
using a 3-week schedule. Chemonaive patients with
advanced or metastatic breast cancer were given paclitaxel
(175 mg/m2) on day 1 and gemcitabine (1200 mg/m2) on
days 1 and 8 every 3 weeks. The overall response rate was
67%, with 22% complete responders. The median time to
tumor progression was 11 months, and the median dura-
tion of response was 18 months.
The results of these studies (Table 4), along with those of
our current study, clearly establish the efficacy of the gem-
citabine and paclitaxel combination in chemonaive and
pretreated MBC patients. At present, anthracycline-based
combinations are the mainstay of chemotherapy in the
early treatment of breast cancer, but their effectiveness
decreases in later treatments in the metastatic setting. The
cardiotoxicity associated with anthracyclines also limits
the total amount of the drug that can be used in a patient.
Thus, there is a strong need to develop newer treatment
regimens that are not cross-resistant with anthracyclines
yet have antitumor activity in MBC. Gemcitabine and
paclitaxel are known to possess considerable cytotoxic
activity individually with minimally overlapping toxicity
profiles. Both drugs act on different cellular targets with
indications of noncross-resistance to each other. In phar-
macokinetic studies, gemcitabine and paclitaxel did not
interfere with each other, and in vitro studies did not dem-
onstrate any synergism between these 2 drugs [23,34].
However, increased accumulation of dFdCTP by paclitaxel
might augment the antitumor activity of gemcitabine in
clinical studies[23]. Based on this information, it is not
unreasonable to expect that the addition of paclitaxel to
gemcitabine may produce additional efficacy that is supe-
rior to either drug given alone. To explore this possibility
further, a phase randomized III trial comparing gemcitab-
ine plus paclitaxel versus paclitaxel alone is currently
under way. The efficacy and toxicity results of this study
will offer significant insight into the clinical implications
of combining these agents in patients with advanced or
metastatic breast cancer.
Conclusion
In conclusion, gemcitabine in combination with paclit-
axel has demonstrated notable activity along with an
acceptable and tolerable safety profile. Further evaluation
of this regimen is warranted in the treatment of metastatic
breast cancer.
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